Xing Wang1, Jianmin Gu2, Cuiling Shao2, Kun Han2, Jian Meng2. 1. Department of Oromaxillofacial Head and Neck Surgery, College of Medicine, Affiliated Xuzhou Hospital, Southeast University, Xuzhou, Jiangsu 221000; Department of Oral Medicine, Peking University School and Hospital of Stomatology, Beijing 100081, China. 2. Department of Oromaxillofacial Head and Neck Surgery, College of Medicine, Affiliated Xuzhou Hospital, Southeast University, Xuzhou, Jiangsu 221000, China.
Abstract
BACKGROUND: A clinical study was conducted to determine the efficacy of nimotuzumab combined with docetaxel, cisplatin, and 5-fluorouracil (TPF) for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) after surgery and conformal radiotherapy. METHODS: Thirty-one HNSCC patients received three courses of chemotherapy every 21 days, at a dose of 75 mg/m2 of docetaxel and cisplatin on day 1 and 750 mg/m2 of 5-fluorouracil on days 1-5 followed by 200 mg/m2/week of nimotuzumab on week 1-2 (day 6-21). RESULTS: After sequential therapy, complete and partial responses were observed in 10 (32.3%) and 17 (54.8%) patients, respectively. The overall response rate was 87.1%. A progression-free survival of 71.2% (95% confidence interval [CI] 51.6%-93.7%) and an overall survival of 78.3% (95% CI 58.9%-89.5%) were achieved at 2nd year. The most common Grade 3-4 toxicities during the complete treatment were lymphopenia (25.8%), neutropenia (22.6%), anemia (12.9%), and diarrhea (16%). In addition, no rash and treatment-related death occurred during this study. CONCLUSIONS: Nimotuzumab in combination with TPF has been well tolerated as a treatment program for locally advanced HNSCC.
BACKGROUND: A clinical study was conducted to determine the efficacy of nimotuzumab combined with docetaxel, cisplatin, and 5-fluorouracil (TPF) for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) after surgery and conformal radiotherapy. METHODS: Thirty-one HNSCC patients received three courses of chemotherapy every 21 days, at a dose of 75 mg/m2 of docetaxel and cisplatin on day 1 and 750 mg/m2 of 5-fluorouracil on days 1-5 followed by 200 mg/m2/week of nimotuzumab on week 1-2 (day 6-21). RESULTS: After sequential therapy, complete and partial responses were observed in 10 (32.3%) and 17 (54.8%) patients, respectively. The overall response rate was 87.1%. A progression-free survival of 71.2% (95% confidence interval [CI] 51.6%-93.7%) and an overall survival of 78.3% (95% CI 58.9%-89.5%) were achieved at 2nd year. The most common Grade 3-4 toxicities during the complete treatment were lymphopenia (25.8%), neutropenia (22.6%), anemia (12.9%), and diarrhea (16%). In addition, no rash and treatment-related death occurred during this study. CONCLUSIONS: Nimotuzumab in combination with TPF has been well tolerated as a treatment program for locally advanced HNSCC.
Entities:
Keywords:
Chemotherapy; epidermal growth factor receptor; head and neck squamous cell carcinoma